Ann: Entitlement Offer Documents, page-2

I can't see a way out of this for the company.

In reality none of the products are close to commercialisation - how many more times are they going to have to tap the market for cash over the next 1-3 years to keep funding these trials?

In the presentation it says "transition from preclinical to clinical stage company in only two years," however when they licensed in the products some of them already had trials ongoing? Nov 2021 investor presentation referenced below.

They've miscalculated in my opinion. Bit off more than they can chew and licensed in too many products. Feel for the various Universities/scientists that have had their products shelved.

I like the premise - gather a suite of radiopharmaceuticals and create a package deal - I just don't believe the planning beyond the initial phase was done well. Happy to be proven wrong.

Best case scenario one of the shots on target has a successful late-stage trial and attracts some interest leading to a sale of the company as a whole.